Cancer Genetics Inc

Cancer Genetics — Q3 2016 Earnings Presentation

15 slides from Cancer Genetics's earnings presentation, Nov 10, 2016

  1. Slide 1: Q3 2016 Earnings Call

    Q3 2016 EARNINGS CALL Nov 10, 2016

  2. Slide 2: Forward-Looking Statements

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growt

  3. Slide 3: Everything we do is focused on one key idea

    EVERYTHING WE DO IS FOCUSED ON 1 KEY IDEA… …DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES IN PRECISION MEDICINE FOR ONCOLOGY DIAGNOSTICS.

  4. Slide 4: Investor Highlights: Cancer Genetics Addresses Key Trends in Oncology

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Large, Global Market Opportunities $458B GLOBAL ONCOLOGY SPEND BY 2030 Global Footprint Created by Highly Strategic M&A 3 TRANSFORMATIVE ACQUISITIONS IN 2014 & 2015 Strong & Growing Partnerships with Leading BioPharma CONTRACTS WITH 8 of 1

  5. Slide 5: 3rd Quarter 2016 Revenue Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call 3rd Quarter 2016 Revenue Highlights 68% REVENUE GROWTHFROM Q3 2015 Q3 TOTAL REVENUE GREW FROM $4.0M TO 2015 2016 $1.5 $4.0 $6.8 $0 $4 $7 3-Year CAGR 65% Q 3 2 0 1 4 Q3 2 0 1 5 Q 3 2 0 1 6 P.5 M M M N u m ber s in $ m illion s Year-over-yea

  6. Slide 6: Revenues By Category

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Revenues By Category BIOPHARMA SERVICES CLINICAL SERVICES DISCOVERY SERVICES 65% 29% 6% Q3 2015 $4.0 Mn  204% increase in clinical test volume over Q3 2015 due to enhanced portfolio in both immuno-oncology testing and our solid tumor cent

  7. Slide 7: Q3 2016 Financial Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Q3 2016 Financial Highlights  Revenues were $6.8 million, a 68% increase over Q3 2015 revenues of $4.0 million Q2 2016, with Biopharma services contributing $3.8 million, Clinical services contributing $2.7 million and discovery services

  8. Slide 8: Q3 2016 Financial Highlights, continued

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Q3 2016 Financial Highlights, continued  Gross profit margins improved by $1.4 million or 12%, to $2.3 million or 34% as compared to only $0.9 million or 22% during the 3rd quarter of 2015.  Operating expenses continue to decrease, with

  9. Slide 9: Path Towards Profitability: Key Trends

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Path Towards Profitability: Key Trends 3.0 4.0 5.0 6.0 7.0 8.0 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Last 5 Quarters - Revenue and Operating Expenses* Revenue Operating Expenses 4.0 5.5 6.1 7.0 6.8 6.5 7.9 7.2 6.7 6.3 * Amounts in $ mill

  10. Slide 10: Q3 2016 Financial Highlights: Expenses and Cost Control

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Q3 2016 Financial Highlights: Expenses and Cost Control  Continued optimization of headcount after the acquisition of Response Genetics, Inc. with a reduction of 50 full time employee equivalents since Q4 2015.  Headcount reduction resul

  11. Slide 11: Q3 2016 Corporate Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Q3 2016 Corporate Highlights  Launched a proprietary comprehensive NGS panel for kidney cancer, FOCUS::Renal™ with CLIA validation to apply in both clinical care and trials by biotech and pharmaceutical companies.  FOCUS::Myeloid™ NGS pa

  12. Slide 12: Q3 2016 Collaboration / Partnership Highlights

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Q3 2016 Collaboration / Partnership Highlights  Personalized medicine company, ApoCell, Inc., partnered with CGI to collaborate on transforming cancer profiling and therapy selection leveraging ApoCell’s proprietary, high-performance liqu

  13. Slide 13: Summary Statement of Operations

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Summary Statement of Operations Income Statement Item ($ in Thousands) Q3 2015 Q2 2016 Q3 2016 Revenue $4,001 $7,000 $6,750 Gross Profit 898 2,716 2,306 Gross Margin (%) 22% 39% 34% Research & Development (R&D) 1,802 1,680 1,594 Sales & Ma

  14. Slide 14: Our Three Pillars of Innovation

    Cancer Genetics, Inc. | NASDAQ: CGIX | Q3 2016 Earnings Call Our Three Pillars of Innovation I. UNIQUE CONTENT VIA PARTNERSHIPS & COLLABORATIONS II. IMMUNO-ONCOLOGY CAPABILITIES THAT ARE INDUSTRY LEADING III. LIQUID BIOPSY HIGH SENSITIVITY ANALYSIS CELL-FREE CTCS AND EXOSOME • Mayo Clinic Oncospire

  15. Slide 15: Cancer Genetics contact and office locations

    WWW.CGIX.COM WWW.CANCERGENETICS.COM CGI Headquarters 201 Route 17 North Rutherford, NJ 07070 Phone: +1 201-528-9200 RUTHERFORD, NJ Research Triangle Park 133 Southcenter Court Morrisville, NC 27569 Phone: +1 919-465-0100 RALEIGH, NC LOS ANGELES, CA 1640 Marengo Street Fourth Floor Los Angeles, CA 90

Cancer Genetics — Q3 2016 Earnings Presentation on 6ix